Hyperbaric Chamber for Parkinson’s Disease: What Research Shows

Parkinson’s disease slowly dismantles the motor system, and current treatments manage symptoms without slowing the underlying damage. That gap drives patients and researchers alike to explore adjunctive approaches, including hyperbaric oxygen therapy (HBOT). The interest is scientifically grounded: Parkinson’s pathology involves mitochondrial dysfunction, oxidative stress, and neuroinflammation, and HBOT is known to influence all three. What the research actually shows, however, is more nuanced than most clinics describe. It is one of several hyperbaric therapy for brain and cognitive conditions currently being explored in clinical research.

What Does the Research Say?

The most comprehensive human data comes from two recent meta-analyses. Bu et al. 2024 analyzed 13 studies with 958 participants drawn from PubMed, Web of Science, Cochrane Library, and Chinese databases through March 2023.¹ Results showed:

• Motor function (UPDRS III): MD = -2.96 (95% CI -4.31 to -1.61, p<0.01) – clinically meaningful reduction in motor symptom severity
• Disease severity (Hoehn-Yahr staging): MD = -0.14 (95% CI -0.26 to -0.02, p<0.01)
• Cognitive function (MoCA): SMD = 0.65 (95% CI 0.45-0.85, p<0.01) – moderate-to-large effect size
• Sleep quality (PSQI): MD = -2.52 (95% CI -2.85 to -2.18, p<0.01)
• Daytime sleepiness (ESS): MD = -3.30 (95% CI -3.77 to -2.83, p<0.01)
• Treatment efficacy rate: OR = 3.18 (95% CI 1.60-6.33, p<0.01) – three times the odds of clinical response

The Pan et al. 2025 meta-analysis specifically focused on non-motor symptoms across 16 studies with 1,324 participants.² HBOT was found to effectively alleviate anxiety (Hamilton Anxiety Scale), depression (Hamilton Depression Scale), cognitive impairments (MoCA, MMSE), sleep disturbances (PSQI, ESS), and swallowing dysfunction. Motor function also improved. Both meta-analyses note significant heterogeneity between studies, and both draw predominantly from Chinese research literature.

Why HBOT May Help: The Dopamine Connection

Parkinson’s disease is defined by the progressive loss of dopaminergic neurons in the substantia nigra. By the time motor symptoms appear, approximately 60-80% of these neurons are already lost. This is the key target HBOT research aims to address.

A 2022 mechanistic study in the MPTP mouse model – the gold-standard Parkinson’s animal model – found that 7 days of HBOT at 2.5 ATA (1 hour daily) produced significant biological effects:³

• Increased TH-positive (dopaminergic) neurons in the substantia nigra
• Enhanced neurotrophic factor BDNF
• Decreased apoptotic (programmed cell death) signaling
• Attenuated inflammatory mediators
• Improved locomotor activity and grip strength
• Upregulated mitochondrial biogenesis signaling through the SIRT-1/PGC-1alpha/TFAM pathway

The SIRT-1/PGC-1alpha pathway is a recognized master regulator of mitochondrial health. Since mitochondrial dysfunction is central to Parkinson’s pathology, this mechanistic finding provides a biologically plausible rationale for the clinical improvements seen in human studies.

Importantly, even mild hyperbaric oxygen – at pressures below standard clinical protocols (1317 hPa, 45% O2, 3 hours, 3x/week for 11 weeks) – significantly preserved dopaminergic neurons and improved balance beam performance in the MPTP mouse model.⁴ This suggests the therapeutic window may be broader than previously assumed and raises questions about whether soft chamber protocols might have some value, though this has not been tested in humans.

What the Research Does Not Show

To be accurate, several important limitations must be stated clearly:

• No Western RCTs: As of May 2026, no large double-blind sham-controlled trials have been conducted outside of China. A systematic review protocol was published in 2024 suggesting one may be forthcoming.
• No dopaminergic neuron preservation confirmed in humans: The neuroprotective effects seen in animal models have not been demonstrated in human tissue or imaging studies.
• Significant protocol heterogeneity: Studies use different pressures, session lengths, and frequencies, making direct comparison difficult.
• HBOT does not replace standard therapy: All clinical evidence positions HBOT as an adjunct to dopaminergic medications (levodopa, dopamine agonists), not as a replacement. Animal studies even suggest combined HBOT plus levodopa may be more effective than either alone.⁵

What Does the HBOT Protocol Look Like?

The human studies in the Bu 2024 meta-analysis typically used:

• Pressure: 2.0-2.5 ATA in clinical hard chambers
• Session duration: 60 minutes
• Frequency: 5 sessions per week
• Course length: 20-40 sessions (4-8 weeks), shorter than protocols used in TBI and cognitive research

Hard chamber facilities are required for these pressures. Soft chambers at 1.3 ATA have not been validated in Parkinson’s research. For comparison, the Harch and Efrati protocols used in TBI and cognitive research use longer courses (40-60 sessions). It is unclear whether longer courses would produce greater or more durable benefits in Parkinson’s.

For more on what sessions look like, visit our HBOT sessions guide. For related neurological applications, see our pages on HBOT for brain injury and HBOT for dementia.

Access and Cost

• Insurance: does not cover HBOT for Parkinson’s (off-label use)
• Cost: A 40-session course costs approximately $6,000-$12,000 out of pocket
• Access: Hard chamber at 2.0+ ATA required. Most sessions take place at specialized HBOT clinics or hospital-based programs

Who Should Not Try HBOT

HBOT is generally safe when administered by trained professionals, but it is not appropriate for everyone. Discuss your full medical history with your provider before starting.

Absolute Contraindications

• Untreated pneumothorax (collapsed lung) – pressure changes can worsen this condition and become life-threatening
• Certain chemotherapy drugs – bleomycin, cisplatin, doxorubicin, and disulfiram may interact dangerously with high-oxygen environments

Relative Contraindications

• Upper respiratory infection or sinus congestion – difficulty equalizing pressure can cause ear or sinus barotrauma
• Seizure disorder – high-pressure oxygen can lower seizure threshold in susceptible individuals
• Chronic obstructive pulmonary disease (COPD) – altered breathing drive may require modified protocols
• High fever – increases the risk of oxygen toxicity
• History of ear surgery or chronic ear problems – pressure equalization may be difficult or risky
• Claustrophobia – may require sedation or use of a multiplace chamber instead
• Pregnancy – insufficient safety data exists for routine use during pregnancy

Talk to Your Doctor First

Even if you do not have the conditions listed above, always consult your physician before starting HBOT, especially if you take insulin, have a pacemaker or implanted device, or are currently taking any medications. For a full overview of HBOT side effects and risks, see our detailed guide.

References

1. Bu S, Liu W, Sheng X, Jin L, Zhao Q. “Hyperbaric Oxygen Therapy Improves Motor Symptoms, Sleep, and Cognitive Dysfunctions in Parkinson’s Disease.” Dementia and Geriatric Cognitive Disorders. 2024. DOI: 10.1159/000542619
2. Pan Z, Tan W, Ran X, et al. “Effect of hyperbaric oxygen therapy for non-motor symptoms among patients with Parkinson’s disease: A systematic review and meta-analysis.” Physiotherapy. 2025. DOI: 10.1177/02692155241310750
3. Hsu HF, Yang YL, Chang WH, et al. “Hyperbaric Oxygen Therapy Improves Parkinson’s Disease by Promoting Mitochondrial Biogenesis via the SIRT-1/PGC-1alpha Pathway.” Biomolecules. 2022;12(5):661. DOI: 10.3390/biom12050661
4. Kusuda Y, Takemura A, Nakano M, Ishihara A. “Mild hyperbaric oxygen inhibits the decrease of dopaminergic neurons in the substantia nigra of mice with MPTP-induced Parkinson’s disease.” Neuroscience Research. 2018;132:58-62.
5. Pan X, Chen C, Huang J, Wei H, Fan Q. “Neuroprotective effect of combined therapy with hyperbaric oxygen and madopar on 6-OHDA-induced Parkinson’s disease in rats.” Neuroscience Letters. 2015;600:220-225. DOI: 10.1016/j.neulet.2015.06.030
6. Atzeni F, et al. “Hyperbaric oxygen therapy in fibromyalgia and diseases involving the CNS.” Clinical and Experimental Rheumatology. 2020.
7. Banou E. “Hyperbaric Oxygen Therapy Effect on ‘Kinesia Paradoxa’ Brain Circuits.” Advances in Experimental Medicine and Biology. 2021. DOI: 10.1007/978-3-030-78787-5_19
8. UHMS. “About Parkinson’s Disease.” UHMS: Approved HBO Indications

Seph Fontane Pennock

Author

Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.

Website